. Primer sequences.
Primer
Sequence 5' → 3' 4.1 ± 0.5 D31V S32C D45V LCI-M4-PP 3.6 ± 0.2 K3R P8Q N9K G10C D19G I24T S27G G35D W44R D45V LCI-M5-PP 2.9 ± 0.4 Q6H Y29F I40T D45A LCI-M6-PP 2.6 ± 0.2 P8L S15R S27C D45G LCI-M7-PP 2.6 ± 0.8 W23R S33T Y36C LCI-M8-PP 2.6 ± 0.4 L4Q K34R E42V LCI-M9-PP 2.6 ± 0.3 I2F K3Q N11S D19G G35C K47R LCI-M10-PP 2.5 ± 0.1 F16L I24S I40T D45Y 2.9 ± 0.1 D31L 2.9 ± 0.2 D31S 2.7 ± 0.3 G35 G35W 3.8 ± 0.5 G35V 3.7 ± 0.4 Figure S1 . Expression and performance of PP-binding peptide LCI variants. SSM variants LCI Y29R and LCI G35V
and generated recombination variants LCI Y29R/G35V were produced in MTP and resulting CFE was used for SDS-PAGE to evaluate expression level (a) and in ABBA screening system to evaluate binding performance (b). 
